title: Carboplatin/paclitaxel or carboplatin/vinorelbine followed by accelerated hyperfractionated conformal radiation therapy: report of a prospective phase I dose escalation trial from the Carolina Conformal Therapy Consortium.
abstract: OBJECTIVE
  To prospectively determine the maximum-tolerated dose of accelerated hyperfractionated conformal radiotherapy (RT; 1.6 Gy bid) for unresectable locally advanced lung cancer (IIB to IIIA/B) following induction carboplatin/paclitaxel (C/T) or carboplatin/vinorelbine (C/N).
  
  
  METHODS
  Induction chemotherapy, C/T or C/N, was followed by escalating doses of conformally-planned RT (73.6 to 86.4 Gy in 6.4-Gy increments). Concurrent boost methods delivered 1.6 and 1.25 Gy bid to the gross and clinical target volumes, respectively.
  
  
  RESULTS
  Between November 1997 and February 2002, 44 patients were enrolled (median age, 59 years; 59% male; stage III, 98%; median tumor size, 4 cm). Thirty-nine patients completed induction chemotherapy: 19 had a partial response, seven progressed, 15 had no response, and three were not assessable. Chemotherapy-associated toxicities were similar in the two chemotherapy groups. The incidence of grade > or = 3 RT-induced toxicity was 1/13, 2/14, and 4/12 at 73.6, 80, and 86.4 Gy, respectively, thus defining the maximum tolerated dose at approximately 80 Gy. Toxicities were in both lung and esophagus and were similar in the two chemotherapy arms. With a median followup of 34 months in the survivors, the actuarial 2-year survival was 47%, the median survival was 18 months. Fifteen patients had tumor relapse: 5 local failures in the high-dose volume, 2 regional failures outside of the high-dose volume, and 8 distant metastases.
  
  
  CONCLUSIONS
  High-dose conformal twice-daily radiation therapy to approximately 80 Gy appears tolerable in well-selected patients with unresectable lung cancer following either C/T or C/N. Dose-limiting toxicities are mainly pulmonary and esophageal.
authors.affiliation: Department of Radiation Oncology, Duke University Medical Center, Durham, NC 27710, USA. marks@radonc.duke.edu
authors.forename: Lawrence B
authors.initials: LB
authors.lastname: Marks
authors.forename: Jennifer
authors.initials: J
authors.lastname: Garst
authors.forename: Mark A
authors.initials: MA
authors.lastname: Socinski
authors.forename: Gregory
authors.initials: G
authors.lastname: Sibley
authors.forename: A William
authors.initials: AW
authors.lastname: Blackstock
authors.forename: James E
authors.initials: JE
authors.lastname: Herndon
authors.forename: Sunmin
authors.initials: S
authors.lastname: Zhou
authors.forename: Timothy
authors.initials: T
authors.lastname: Shafman
authors.forename: Andrea
authors.initials: A
authors.lastname: Tisch
authors.forename: Robert
authors.initials: R
authors.lastname: Clough
authors.forename: Xiaoli
authors.initials: X
authors.lastname: Yu
authors.forename: Andrew
authors.initials: A
authors.lastname: Turrisi
authors.forename: Mitchell
authors.initials: M
authors.lastname: Anscher
authors.forename: Jeffrey
authors.initials: J
authors.lastname: Crawford
authors.forename: Julian
authors.initials: J
authors.lastname: Rosenman
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use*; D016190:Carboplatin / Q000008:administration & dosage / Q000009:adverse effects; D002289:Carcinoma, Non-Small-Cell Lung / Q000188:drug therapy* / Q000532:radiotherapy*; D003131:Combined Modality Therapy; D019583:Dose Fractionation, Radiation; D004947:Esophagus / Q000473:pathology / Q000528:radiation effects; D005260:Female; D006801:Humans; D008175:Lung Neoplasms / Q000188:drug therapy* / Q000532:radiotherapy*; D008297:Male; D008875:Middle Aged; D017239:Paclitaxel / Q000008:administration & dosage / Q000009:adverse effects; D016016:Proportional Hazards Models; D020266:Radiotherapy, Conformal; D016019:Survival Analysis; D016896:Treatment Outcome; D014747:Vinblastine / Q000008:administration & dosage / Q000009:adverse effects / Q000031:analogs & derivatives*; D000077235:Vinorelbine
chemical_list: D014747:Vinblastine; D016190:Carboplatin; D017239:Paclitaxel; D000077235:Vinorelbine